

## ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines

L.M. Lucas<sup>1</sup>, R.L. Cullum<sup>1,2</sup>, J.N. Woggerman<sup>1,3</sup>, V. Dwivedi<sup>1</sup>, J.A. Markham<sup>1</sup>, C.M. Kelley<sup>1</sup>,  
E.L. Knerr<sup>1,4</sup>, L.J. Cook<sup>1,4</sup>, H.C. Lucas II<sup>1</sup>, D.S. Waits<sup>4</sup>, T.M. Ghosh<sup>1</sup>, K.M. Halanych<sup>4,5</sup>, R.B. Gupta<sup>2,6</sup>,  
and D.J. Riese II<sup>1,7#</sup>

<sup>1</sup>Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849 USA

<sup>2</sup>Department of Chemical Engineering, Auburn University, Auburn, AL 36849 USA

<sup>3</sup>Department of Chemistry and Biochemistry, Auburn University, Auburn, AL 36849 USA

<sup>4</sup>Department of Biological Sciences, Auburn University, Auburn, AL 36849 USA

<sup>5</sup>Center for Marine Science, University of North Carolina-Wilmington, Wilmington, NC 28403  
USA

<sup>6</sup>Department of Chemical and Life Science Engineering, Virginia Commonwealth University,  
Richmond, VA 23284

<sup>7</sup>O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham,  
AL 35233 USA

#Corresponding Author:

David J. Riese II

Department of Drug Discovery and Development

Harrison College of Pharmacy

Auburn University

Walker 3211g

Auburn, AL. 36849

[driese@auburn.edu](mailto:driese@auburn.edu)

334-844-8358

## Abstract

Metastatic skin cutaneous melanomas remain a significant clinical problem. In particular, those melanomas that do not contain a gain-of-function *BRAF* allele remain challenging to treat because of the paucity of targets for effective therapeutic intervention. Thus, here we investigate the role of the *ERBB4* receptor tyrosine kinase in skin cutaneous melanomas that contain wild-type *BRAF* alleles (“*BRAF* WT melanomas”). We have performed *in silico* analyses of a public repository (The Cancer Genome Atlas - TCGA) of skin cutaneous melanoma gene expression and mutation data (TCGA-SKCM data set). These analyses demonstrate that elevated *ERBB4* transcription strongly correlates with *RAS* gene or *NF1* mutations that stimulate RAS signaling. Thus, these results have led us to hypothesize that elevated *ERBB4* signaling which cooperates with elevated RAS signaling to drive *BRAF* WT melanomas. We have tested this hypothesis using commercially available *BRAF* WT melanoma cell lines. Ectopic expression of wild-type *ERBB4* stimulates clonogenic proliferation of the IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 *BRAF* WT melanoma cell lines, whereas ectopic expression of a dominant-negative (K751M) *ERBB4* mutant allele inhibits clonogenic proliferation of these same cell lines. Ectopic expression of a dominant-negative *ERBB4* mutant allele inhibits anchorage-independent proliferation of MEL-JUSO cells and ectopic expression of a dominant-negative *ERBB2* mutant alleles inhibits clonogenic proliferation of MEL-JUSO cells. These data suggest that elevated signaling by *ERBB4*-*ERBB2* heterodimers cooperates with elevated RAS signaling to drive the proliferation of some *BRAF* WT tumors and that combination therapies that target these two signaling pathways may be effective against these *BRAF* WT tumors.

## Introduction

BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors (“checkpoint inhibitors”) are transforming the treatment of advanced skin cutaneous melanomas that possess oncogenic *BRAF* mutations (“*BRAF* mutant melanomas”) [1]. A contemporary clinical trial reports 34% five-year survival of patients with advanced *BRAF* mutant skin cutaneous melanomas treated with BRAF and MEK inhibitors [2, 3]. Another clinical trial reports 60% five-year survival of patients with advanced *BRAF* mutant skin cutaneous melanomas treated with a combination of immune checkpoint inhibitors [2, 4]. Finally, combining immune checkpoint inhibitors with BRAF and MEK inhibitors will likely lead to further improvements in survival [5].

Unfortunately, approximately 50% of advanced skin cutaneous melanomas possess wild-type *BRAF* alleles, and contemporary treatments of advanced skin cutaneous melanomas that contain wild-type *BRAF* (“*BRAF* WT melanomas”) have yielded less impressive results [1]. In part, these less impressive results are because of a paucity of actionable targets for the effective (targeted) treatment of these tumors [6]. For example, despite the fact that a majority of *BRAF* WT melanomas possess a gain-of-function *RAS* allele or a loss-of-function *NF1* allele, these tumors do not respond to MEK inhibitors [1]. Moreover, the five-year survival of patients with advanced *BRAF* WT skin cutaneous melanomas treated with immune checkpoint inhibitors is only 48%, less than the 60% experienced by patients with advanced *BRAF* mutant skin cutaneous melanomas in a parallel study [4].

Hence, we have attempted to address this gap in treatment efficacy by evaluating the ERBB4 receptor tyrosine kinase as a candidate target in *BRAF* WT skin cutaneous melanomas. Should ERBB4 prove to be a reasonable target in *BRAF* WT skin cutaneous melanomas, we anticipate that strategies that target ERBB4 signaling could be used in combination with immune checkpoint inhibitors to treat these tumors, analogous to what has been proposed for the treatment of *BRAF* mutant skin cutaneous melanomas.

ERBB4 (HER4) is a member of the ERBB family of receptor tyrosine kinases (RTKs), which includes the epidermal growth factor receptor (EGFR), ERBB2 (HER2/Neu), and ERBB3 (HER3). ERBB4 possesses extracellular ligand-binding domains, a single-pass hydrophobic transmembrane domain, an intracellular tyrosine kinase domain, and intracellular tyrosine residues that function as phosphorylation sites. Ligand binding to EGFR, ERBB3, or ERBB4 stabilizes the receptor extracellular domains in an open conformation competent for symmetrical homodimerization and heterodimerization of the receptor extracellular domains. The dimerization of the extracellular domains enables asymmetrical dimerization of the receptor cytoplasmic domains. Phosphorylation of one receptor monomer on tyrosine residues by the tyrosine kinase domain of the other receptor monomer (“cross-phosphorylation”) ensues. This tyrosine phosphorylation creates binding sites for effector proteins and activation of downstream signaling pathways [7].

Elevated signaling by an RTK is a hallmark of many types of cancer. Hence, RTK overexpression, ligand overexpression, and gain-of-function mutations in an RTK gene are all mechanisms for pathologic, elevated RTK signaling. Indeed, EGFR and ERBB2 have been validated as targets for therapeutic intervention in numerous types of tumors; monoclonal antibodies and small molecular tyrosine kinase inhibitors have been approved to treat tumors

dependent on these receptors [8-23]. It appears that ERBB3, particularly in the context of ERBB3-ERBB2 heterodimers, also drives various human tumors [24, 25].

In contrast, the role that ERBB4 plays in human tumors remains ambiguous. Part of the ambiguity reflects that an ERBB4 homodimer can function as a tumor suppressor, whereas an ERBB4-EGFR or ERBB4-ERBB2 heterodimer can drive tumor cell proliferation or aggressiveness [7]. Hence, in this work, we attempt to resolve this ambiguity by testing the hypothesis that ERBB4 is sufficient and necessary for the proliferation of *BRAF* WT skin cutaneous melanoma cell lines.

## Results

**A. *BRAF* WT melanomas do not appear to be less aggressive than *BRAF* V600X melanomas.** The Cancer Genome Atlas – Skin Cutaneous Melanoma (TCGA-SKCM) dataset contains outcome, gene expression, and mutation data for hundreds of skin cutaneous melanomas [26]. We analyzed the TCGA-SKCM dataset to look for meaningful differences between the group of skin cutaneous melanoma patients whose tumors possess *BRAF* WT alleles (“*BRAF* WT melanomas”) and the group of melanoma patients whose tumors have a gain-of-function *BRAF* V600X allele (“*BRAF* V600X melanomas”). **Table 1** compares these two groups.

*BRAF* WT melanomas account for a slightly greater percentage of cases in the TCGA-SKCM dataset than *BRAF* V600X melanomas, suggesting that treating *BRAF* WT melanomas is a significant clinical challenge. Furthermore, Chi-square analysis indicates that a slightly ( $P=0.1252$ ) greater percentage of *BRAF* WT melanoma patients had died when the dataset was closed than *BRAF* V600X melanoma patients (**Table 2a**). Moreover, Chi-square analysis indicates that the AJCC pathologic stage of the *BRAF* WT melanomas was not significantly different ( $P=0.6842$ ) from the AJCC pathologic stage of the *BRAF* V600X melanomas (**Table 2b**). Therefore, *BRAF* WT melanomas do not appear to be less aggressive than *BRAF* V600X melanomas. Hence, these *BRAF* WT melanomas pose a significant clinical problem, particularly because there is currently no targeted therapeutic strategy for these tumors.

Gender is associated with disparate melanoma risk and outcomes [27-36]. In particular, it appears that male melanoma patients experience less favorable outcomes. In part, these appear to be due to increased tumor evasion of immunosurveillance and decreased response to immune checkpoint inhibitors. In the *BRAF* WT cases of the ATCC-SKCM dataset, male patients appear to be associated with significantly worse outcomes than female patients (**Table 2c**). However, this gender disparity is not significant among the *BRAF* V600X cases (data not shown).

**B. Elevated *ERBB4* expression is correlated with *RAS* or *NF1* mutations in *BRAF* WT melanomas.** Gain-of-function *RAS* gene mutations occur in about 30% of skin cutaneous melanomas, and loss-of-function mutations in *NF1* occur in about 20% of skin cutaneous melanomas. Moreover, gain-of-function *BRAF* mutations, gain-of-function *RAS* gene mutations, and loss-of-function *NF1* mutations are largely mutually exclusive in skin cutaneous melanomas [37].

Receptor tyrosine kinases typically stimulate *RAS* pathway signaling [38-44]. Hence, we predicted that elevated *ERBB4* expression (which is likely to cause elevated *ERBB4* signaling) would be inversely correlated with gain-of-function *RAS* gene mutations or loss-of-function *NF1* mutations in *BRAF* WT melanomas of the TCGA-SKCM dataset. *ERBB4* transcription and *NF1*/*RAS* gene expression and mutation data were available for 178 *BRAF* WT melanomas (**Figure 1**). Surprisingly, Chi-square analysis indicates that *ERBB4* transcription greater than or equal to 0.12 (22 melanomas – 12% of the total) is positively correlated ( $P=0.0057$ ) with a gain-of-function *RAS* gene mutation or a loss-of-function *NF1* mutation in these *BRAF* WT melanomas (**Table 2d**). This correlation suggests that elevated *ERBB4* signaling does not stimulate *RAS* pathway signaling; instead, this correlation suggests that *ERBB4* signaling

stimulates a pathway that cooperates with elevated RAS pathway signaling to drive *BRAF* WT melanomas.

**C. Four commercially available *BRAF* WT melanoma cell lines appear to be appropriate for analyses of *ERBB4* function.** A prior report of *ERBB4* function in human skin cutaneous melanomas primarily utilized proprietary human skin cutaneous melanoma cell lines [45]. This may have contributed to the failure of others to extend the findings of this work. Hence, we have used the Broad Institute Cancer Cell Line Encyclopedia (CCLE) [46] to identify six commercially available *BRAF* WT melanoma cell lines: COLO-792 [47], HMCB [48], IPC-298 [49], MEL-JUSO [50], MeWo [51], and SK-MEL-2 [52]. The IPC-298, MEL-JUSO, MeWo, and SK-MEL2 cell lines are easily propagated using standard cell culture media and conditions, and our experiments utilize these four cell lines. The IPC-298 and MEL-JUSO cell lines are each derived from the primary melanoma of a female patient, whereas the MeWo and SK-MEL-2 cell lines are each derived from a melanoma metastasis of a male patient (Table 3). RNAseq data from the Broad Institute CCLE indicate that these cell lines do not contain gain-of-function mutations in *BRAF* or *PIK3CA*, nor loss-of-function mutations in *PTEN*; however, they do contain driver mutations in *NRAS*, *HRAS*, or *NF1*. Hence, if the malignant phenotypes of these cell lines are dependent on elevated *ERBB4* signaling, this elevated *ERBB4* signaling may stimulate phosphatidylinositol-3 kinase (PI3K) pathway signaling, which would cooperate with elevated RAS pathway signaling to drive the malignant phenotypes. This hypothesis is supported by our observation that the coupling of ligand-induced *ERBB4*-EGFR heterodimers to interleukin 3-independent proliferation in BaF3 cells is dependent on *ERBB4* coupling to the PI3K pathway [53].

RNAseq data from the Broad Institute CCLE also indicate that these cell lines exhibit different patterns of *ERBB* and *ERBB4* ligand gene transcription (Table 3). These patterns do not appear to be specific to gender or to primary or metastatic tumors. Furthermore, there does not appear to be any correlation between these patterns of gene expression and the absence or presence of an *ERBB4* mutation.

**D. The canonical *ERBB4* JMa/CYT1 isoform appears to be appropriate for studying *ERBB4* function in *BRAF* WT melanoma cell lines.** The data presented thus far suggest that *ERBB4* signaling drives the proliferation of *BRAF* WT tumors. Thus, we proposed to test whether expression of the wild-type (WT) *ERBB4* gene (cDNA) stimulates the proliferation of *BRAF* WT cell lines and whether expression of a dominant-negative (DN) *ERBB4* mutant inhibits the proliferation of *BRAF* WT cell lines. However, the *ERBB4* gene encodes four alternatively-spliced transcripts [7]. The JMa isoforms encode a TACE cleavage site in the extracellular juxtamembrane region, whereas the JMb isoforms lack the TACE cleavage site and flanking amino acids. The CYT1 (CTa) isoforms encode a PPAY amino acid sequence that binds WWOX/YAP proteins; phosphorylation of the tyrosine residue within this sequence creates a binding site for the p85 regulatory subunit of PI3K. The CYT2 (CTb) isoforms lack the PPAY amino acid sequence and flanking amino acids. To establish which *ERBB4* splicing isoform should be utilized in our experiments, we generated the *ERBB4* cDNA from MeWo RNA. We

chose MeWo cells for this experiment because they exhibit more *ERBB4* transcription than the other three *BRAF* WT melanoma cell lines (Table 3). We used PCR to amplify the region of the *ERBB4* cDNA that distinguishes between JMa and JMb isoforms and the region of the *ERBB4* cDNA that distinguishes between CYT1 and CYT2 isoforms. The size of the JMa/b and CYT1/2 amplicons generated using the *ERBB4* cDNA from the MeWo cells matches the size of the corresponding amplicons generated using an *ERBB4* JMa/CYT1 cDNA plasmid (Figure 2). Thus, MeWo cells express the canonical JMa/CYT1 *ERBB4* splicing isoform and it is appropriate to use the canonical JMa/CYT1 *ERBB4* splicing isoform to study *ERBB4* function in MeWo and other *BRAF* WT melanoma cell lines.

**E. The *ERBB4* K751M mutant exhibits decreased tyrosine phosphorylation, enabling it to function as a dominant negative mutant.** The EGFR K721A mutant protein lacks tyrosine kinase activity [54], thereby enabling it to function as a dominant negative [55-58] by competitively inhibiting tyrosine phosphorylation by an endogenous, wild-type EGFR molecule. Likewise, the *ERBB2* K753A mutant protein lacks tyrosine kinase activity [59-62], thereby enabling it to function as a dominant negative [62] by competitively inhibiting tyrosine phosphorylation by an endogenous, wild-type *ERBB2* molecule. Therefore, we sought to confirm that the analogous *ERBB4* K751M mutant protein lacks tyrosine kinase activity and would therefore antagonize signaling by endogenous *ERBB4* proteins in *BRAF* WT melanoma cell lines. We compared *ERBB4* protein expression and tyrosine phosphorylation in PA317 cells infected with the LXS vector control retrovirus, the LXS-*ERBB4*-WT retrovirus, and the LXS-*ERBB4*-K751M retrovirus (Figure 3). PA317 cells that express the *ERBB4* K751M mutant protein exhibit markedly less *ERBB4* tyrosine phosphorylation than cells that express the wild-type *ERBB4* protein. This suggests that the *ERBB4* K751M mutant protein lacks tyrosine kinase activity and that the *ERBB4* K751M mutant allele functions as a dominant negative.

**F. *ERBB4* is sufficient and necessary for clonogenic proliferation of IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 human *BRAF* WT melanoma cell lines.** We have previously used clonogenic proliferation assays to measure the effects of *ERBB4* signaling on human prostate [63, 64], breast [64, 65], and pancreatic [66] tumor cell lines. Therefore, we infected IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 *BRAF* WT melanoma cells (Table 3a) with a recombinant amphotropic retrovirus that expresses wild-type *ERBB4* (LXS-*ERBB4*-WT), a recombinant amphotropic retrovirus that expresses the *ERBB4* K751M dominant-negative mutant allele (LXS-*ERBB4*-DN), the vector control amphotropic retrovirus (LXS), or a mock virus preparation. Because the LXS recombinant retroviral vector contains a neomycin resistance gene, we selected infected cells using G418. Infection of MEL-JUSO cells with LXS-*ERBB4*-WT results in greater clonogenic proliferation than infection with the LXS control retrovirus. Likewise, infection of MEL-JUSO cells with LXS-*ERBB4*-DN results in less clonogenic proliferation than infection with the LXS control retrovirus (Figure 4). Qualitatively similar results were observed when infecting MeWo, IPC-298, and SK-MEL-2 cells (data not shown).

To quantitatively assess the effects of *ERBB4* WT and *ERBB4* DN on the clonogenic proliferation of *BRAF* WT melanoma cell lines, in parallel we infected C127 mouse fibroblast



cells, which do not endogenously express ERBB4 and do not respond to ERBB4 signaling (data not shown and [63-68]). Relative to the LXS vector control (100%), *ERBB4* WT causes a modest increase in clonogenic proliferation of SK-MEL-2 (159%) cells, a greater increase in the clonogenic proliferation of MEL-JUSO (389%) and MeWo (563%) cells, and a profound increase in the clonogenic proliferation of IPC-298 (1340%) cells (**Table 4**). All of these increases are statistically significant at  $p < 0.05$  (one-tailed).

Likewise, relative to the LXS vector control (100%), *ERBB4* DN causes a modest decrease in clonogenic proliferation of IPC-298 cells (64%). *ERBB4* DN causes a more pronounced decrease in clonogenic proliferation of the SK-MEL-2 (47%), MEL-JUSO (35%), and MeWo (29%) cells. All of these decreases are statistically significant at  $p < 0.05$  (one-tailed).

These results suggest that *ERBB4* is both sufficient and necessary for clonogenic proliferation of the four *BRAF* WT melanoma cell lines and that ERBB4 signaling is a driver of *BRAF* WT melanomas.

**F. *ERBB4* is necessary for anchorage-independent proliferation of the MEL-JUSO *BRAF* WT melanoma cell line.** We have examined the effects of the *ERBB4* WT and *ERBB4* DN alleles on other characteristics of the MEL-JUSO cell line. Neither the *ERBB4* WT allele nor the *ERBB4* DN allele affects the growth rate or saturation density of the MEL-JUSO cell line (data not shown). Moreover, the *ERBB4* WT allele does not affect the anchorage-independent proliferation of MEL-JUSO cells (**Table 5**). However, the *ERBB4* DN allele causes a decrease in the size of anchorage-independent colonies of MEL-JUSO cells (**Figure 5**). This decrease is statistically significant (Table 5), suggesting that *ERBB4* is necessary for anchorage-independent proliferation of the MEL-JUSO *BRAF* WT melanoma cell line.

**G. *ERBB2*, but not *EGFR*, is necessary for clonogenic proliferation of the MEL-JUSO *BRAF* WT melanoma cell line.** In general, ERBB4 homodimers inhibit cell proliferation, whereas ERBB4-EGFR and ERBB4-ERBB2 heterodimers stimulate cell proliferation [7, 53, 59, 63-66, 68-73]. Therefore, we hypothesized that *EGFR* or *ERBB2* might also be sufficient and necessary for clonogenic proliferation of the MEL-JUSO *BRAF* WT melanoma cell line.

We infected MEL-JUSO and C127 cells with recombinant amphotropic retroviruses that express wild-type *EGFR* (LXS-EGFR-WT) [59, 71], the *EGFR* K721A dominant-negative (DN) mutant allele (LXS-EGFR-DN) [59], wild-type ERBB2 (LXS-ERBB2-WT) [59, 71], the ERBB2 K753A dominant-negative mutant allele (LXS-ERBB2-DN) [59], wild-type ERBB4 (LXS-ERBB4-WT) or the LXS vector control. We quantified clonogenic proliferation (**Table 6**) as described elsewhere. The *EGFR* WT and *ERBB2* WT alleles stimulate clonogenic proliferation of MEL-JUSO cells. Clonogenic proliferation is inhibited by the *ERBB2* DN allele, but not the *EGFR* DN allele. There is no ligand for ERBB2 and the MEL-JUSO cells exhibit transcription of the *NRG1*, *NRG2*, and *HBEGF* genes, all of which encode a ligand for ERBB4 (**Table 3**). Thus, it appears that MEL-JUSO cells exhibit endogenous ligand-induced signaling by ERBB4-ERBB2 heterodimers, which cooperates with elevated RAS signaling to drive the proliferation of these cells.



## **Materials and Methods**

**A. Analysis of the TCGA-SKCM dataset.** We obtained the following data for all 470 cases of the TCGA-SKCM dataset: gender; race; ethnicity; vital status; age at diagnosis; AJCC pathologic stage at diagnosis; primary tumor site; days to death; copy number variation for *ERBB4*; mutation status of *BRAF*, *HRAS*, *NRAS*, *KRAS*, *NF1*, *EGFR*, *ERBB2*, *ERBB3*, *ERBB4*, *PIK3CA*, and *PTEN*; and transcription of *AKT1*, *AKT2*, *AKT3*, *PTEN*, *PIK3CA*, *EGFR*, *ERBB2*, *ERBB3*, *ERBB4*, *NRG1*, *NRG2*, *HBEGF*, *BTC*, and *EREG* [26]. The TCGA-SKCM dataset is publicly available through the NIH/NCI Genomic Data Commons (GDC) portal [74]. The R statistical computing and graphics environment software [75] was used to reorganize the dataset. Statistical analyses were performed using GraphPad Prism [76] and Microsoft Excel [77].

**B. Cell lines and cell culture.** The mouse C127 fibroblast cell line [78], the  $\psi$ 2 ectropic recombinant retrovirus packaging cell line [79], and the PA317 amphotropic recombinant retrovirus packaging cell line [80] are generous gifts of Daniel DiMaio (Yale University). These cells were cultured essentially as described previously [63, 78-82]. The MEL-JUSO [50] and IPC-298 [49] human *BRAF* WT melanoma cell lines were obtained from DSMZ [83] (Braunschweig, Germany) and were cultured as recommended by the vendor. The MeWo [51] and SK-MEL-2 human *BRAF* WT melanoma cell lines were obtained from the American Type Culture Collection (ATCC - Manassas, VA) [84] and were cultured as recommended by the vendor. Cell culture media, sera, and supplements were obtained from Cytiva [85] (Marlborough, VA). G418 was obtained from Corning [86] (Corning, NY). Gene mutation and transcription data for the cell lines were obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) [46].

**C. Recombinant retroviruses.** The recombinant amphotropic retroviruses LXS<sub>N</sub> [87], LXS<sub>N</sub>-ERBB4-WT [71], LXS<sub>N</sub>-ERBB4-K751M (LXS<sub>N</sub>-ERBB4-DN) [59, 65], LXS<sub>N</sub>-EGFR-WT [59, 71], LXS<sub>N</sub>-EGFR-K721A (LXS<sub>N</sub>-EGFR-DN) [59], LXS<sub>N</sub>-ERBB2-WT [59, 71], and LXS<sub>N</sub>-ERBB2-K753A (LXS<sub>N</sub>-ERBB2-DN) [59] were packaged using the  $\psi$ 2 ecotropic retrovirus packaging cell line and the PA317 amphotropic retrovirus packaging cell line essentially as previously described [63, 82]. Briefly, because we wished to infect both murine and human cells, high titer recombinant amphotropic retrovirus stocks were required. Thus, the aforementioned recombinant retroviral plasmids were transfected using calcium phosphate into the  $\psi$ 2 ecotropic retrovirus packaging cell line. Because the pLXS<sub>N</sub> recombinant retrovirus vector contains the neomycin resistance gene, stably transfected  $\psi$ 2 cells were selected using G418. For each recombinant retrovirus construct, the colonies of stably transfected  $\psi$ 2 cells were pooled and expanded. The conditioned medium of each resulting  $\psi$ 2 cell line typically contains a low concentration ( $\sim 10^4$  infectious units/mL) of recombinant ecotropic retrovirus. (Presumably this low titer is due to relatively inefficient packaging of retroviral genomes arising from transfected concatemeric plasmid DNA.) The PA317 amphotropic retrovirus packaging cell line was infected with each of these low-titer ecotropic retrovirus stocks. Stably infected PA317 cells were selected using G418 and these colonies were pooled and expanded. The conditioned medium of each resulting PA317 cell line typically contains a high concentration ( $\sim 10^6$  infectious units/mL) of amphotropic retrovirus. (Presumably this high titer is due to relatively efficient packaging of

retroviral genomes arising from retrovirus infection.) These recombinant retroviruses were titered by infecting mouse C127 fibroblasts and selecting for stably infected cells using G418. Colonies of stably infected cells were manually counted and the number of G418-resistant colonies was divided by the volume of retrovirus used in the infection to determine the titer of each retrovirus stock.

**D. Clonogenic proliferation assays.** C127, IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 cells were infected with 500, 20000, 3000, 3000, and 20000 (respectively) infectious units (titered using C127 cells) of amphotropic retroviruses essentially as published [63-68]. Infected cells were selected using 800 ug/mL G418. The resulting colonies of G418-resistant cells were stained using Giemsa when distinct (typically 8-17 days later). Colonies were counted manually and plates were digitized for archival purposes. C127 infections served as controls for viral titer and clonogenic proliferation efficiency was calculated as previously described [63]. Briefly, we calculated the recombinant retroviral titer for each combination of cell line and virus. For each trial, we calculated the efficiency of clonogenic proliferation in the infected IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 cells by dividing the recombinant retroviral titer in each of these cell lines by the corresponding recombinant retroviral titer in the C127 cell line. For each of the subject cell lines, the efficiency of the subject retroviruses was normalized to the efficiency of the LXS vector control retrovirus in that same cell line. We report the average efficiency of clonogenic proliferation over a minimum of four independent trials. We used ANOVA to determine whether the efficiency of clonogenic proliferation of the *BRAF* WT melanoma cell lines infected with the subject retroviruses is significantly different from the efficiency of clonogenic proliferation of these cells infected with the vector control LXS virus. We used a p-value threshold of <0.05 (1-tailed).

**E. Immunoprecipitation and immunoblotting.** We performed ERBB4 immunoprecipitation and immunoblotting essentially as described [65, 67, 68, 71]. PA317 cell lines that had been stably infected with the LXS vector control recombinant retrovirus, the LXS-ERBB4-WT recombinant retrovirus, or the LXS-ERBB4-DN recombinant retrovirus were grown to confluence. Approximately  $2 \times 10^7$  cells were lysed on ice in 2 mL of ice-cold EBC lysis buffer (50 mM Tris, pH 7.4; 120 mM NaCl; 0.5% Igepal CA-630) supplemented with the protease inhibitor aprotinin (final concentration of  $\sim 100$  KIU/mL) and the protein phosphatase inhibitor sodium orthovanadate (final concentration of 1 mM). Centrifugation ( $14000 \text{ g} \cdot \text{min}$  at  $4^\circ \text{C}$ ) cleared the lysates of intact nuclei and other debris. A Bradford assay was used to determine the protein concentration of the cleared lysates.

ERBB4 was immunoprecipitated from 1 mg of lysate diluted to a final concentration of 1 mg/mL. We used 10 uL of the anti-ERBB4 mouse monoclonal antibody SC-8050 (Santa Cruz Biotechnology) and 30 uL of a 1:1 suspension (in lysis buffer) of Protein A Sepharose Beads (17-0780-01; Sigma-Aldrich). The immunoprecipitation reactions were incubated at  $4^\circ \text{C}$  for 2 hours on a rocking platform. Afterward, the beads were collected by centrifugation ( $14000 \text{ g} \cdot \text{min}$  at  $4^\circ \text{C}$ ) and washed three times with 500 uL ice-cold NET-N (20 mM Tris, pH 8.0; 100 mM NaCl; 1 mM EDTA, pH 8.0; 0.5% Igepal CA-630) supplemented with the protease inhibitor aprotinin

(final concentration of ~100 KIU/mL) and the protein phosphatase inhibitor sodium orthovanadate (final concentration of 1 mM).

Following the last wash step, the precipitated proteins were eluted from the beads by adding 80  $\mu$ L of protein sample buffer (4% SDS; 0.1 M DTT; 0.3 M Tris, pH 7.4; 20% glycerol; 0.04% bromphenol blue; 10% 2-mercaptoethanol). The samples were mixed using a vortex mixer and boiled for 5 minutes. The beads were collected by centrifugation (14000  $g \cdot \text{min}$  at room temperature) to permit retrieval of the eluted proteins.

The eluted proteins were resolved by SDS-PAGE using a 7.5% acrylamide gel and electrotransferred (200 mA for >12 hours) to 0.2  $\mu$ m PVDF in a wet tank transfer system (TE-42; Hoefer) containing a transfer buffer consisting of 20% methanol, 25 mM Tris base, 192 mM glycine, 0.09375 % SDS, and 0.01 % sodium orthovanadate. The blot was rinsed three times for 5 minutes at room temperature using TBS-T (10 mM Tris, pH 7.4; 9 g/L NaCl; 0.05% Tween-20), then blocked for two hours at room temperature on a rocking platform using 5% non-fat dried milk in TBS-T. If the blot was to be probed using an anti-phosphotyrosine antibody, the blot was blocked for two hours at room temperature on a rocking platform using 5% BSA and 0.01% sodium azide in TBS-T.

The ERBB4 blots were incubated for two hours at room temperature on a rocking platform with an anti-ERBB4 rabbit monoclonal antibody (4795S – Cell Signaling Technology) diluted 1:1000 in 5% non-fat dried milk in TBS-T. The blots were washed 5 times with TBS-T for 5 minutes at room temperature on a rotating platform. The blots were then probed with a goat anti-rabbit antibody conjugated with horseradish peroxidase (31460 - ThermoFisher). Antibody binding was detected using enhanced chemiluminescence (Cytiva) and documented using a BioRad Chemidoc MP imaging system.

The phosphotyrosine blots were incubated for two hours at room temperature on a rocking platform with the anti-phosphotyrosine mouse monoclonal antibody 4G10 (made in-house from hybridoma PTA-6854; ATCC) diluted empirically in 5% BSA and 0.01% sodium azide in TBS-T. The blots were washed 5 times with TBS-T for 5 minutes at room temperature on a rotating platform. The blots were then probed with a goat anti-mouse antibody conjugated with horseradish peroxidase (31430 - ThermoFisher). Antibody binding was detected using enhanced chemiluminescence (Cytiva) and documented using a BioRad Chemidoc MP imaging system.

**F. Anchorage-independent proliferation assay.** We performed this assay essentially as described [66, 78, 88]. Briefly, for each MEL-JUSO stably infected cell line, 20,000 cells were seeded in a 60 mm cell culture dish in a semi-solid medium consisting of RPMI-1640 supplemented with 10% fetal bovine serum, 500  $\mu$ g/mL G418, and 0.3% low-melting point (LMP) agarose. Additional LMP agarose medium was added to the plates every four days to prevent the cultures from drying out. Fourteen days after seeding, nine randomly selected microscopic fields were digitally photographed. We used NIH Image J [89] to measure the diameter of each anchorage-independent colony of cells. Approximately 8-12 colonies were found in each photograph. Thus, for each trial, approximately 100 colonies were measured for

each cell line. We pooled the data from three independent trials, resulting in approximately 300 colonies for each cell line. A t-test was performed to determine whether differences in average colony size are statistically different.

## **Discussion**

**A. Elevated ERBB4 signaling appears to drive BRAF WT melanomas.** Our data suggest that approximately 12% of *BRAF* WT melanomas exhibit elevated endogenous *ERBB4* transcription, which presumably results in elevated ERBB4 signaling. Elevated endogenous ERBB4 expression is significantly correlated with *NF1/RAS* gene tumor driver mutations. Consequently, we postulated that elevated ERBB4 signaling cooperates with elevated RAS signaling to drive *BRAF* WT melanomas. We tested this hypothesis by measuring the effects of exogenous expression of the WT *ERBB4* allele or an *ERBB4* DN mutant allele on the clonogenic proliferation of *BRAF* WT melanoma cell lines.

WT *ERBB4* stimulates clonogenic proliferation of IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 *BRAF* WT melanoma cells. Moreover, the *ERBB4* DN (K751M) mutant allele inhibits clonogenic proliferation of these same cell lines. These results indicate that ERBB4 is sufficient and necessary for the clonogenic proliferation of these *BRAF* WT melanoma cell lines.

Numerous *ERBB4* mutant alleles have been found in melanomas and other human tumor samples [7]. The data presented here suggest that some of these mutants exhibit a gain-of-function phenotype that enables them to serve as tumor drivers. We will test that hypothesis.

**B. RAS pathway mutations and elevated heterotypic ERBB4 signaling suggest strategies for treating BRAF WT melanomas.** It is commonly accepted that ERBB4 homodimers inhibit cell proliferation, whereas ERBB4-EGFR or ERBB4-ERBB2 heterodimers stimulate cell proliferation [7]. Likewise, published data [53, 59, 71] and data shown here suggest that elevated heterotypic ERBB4 signaling (by ERBB4-ERBB2 or ERBB4-EGFR heterodimers) causes increased PI3K signaling, which cooperates with elevated RAS signaling to drive the proliferation of *BRAF* WT melanomas (Figure 6). Thus, we predict that ERBB4-dependent, *BRAF* WT melanomas will respond to a combination of a PI3K inhibitor with a MEK inhibitor. However, given the toxicity of PI3K inhibitors [90, 91], combining a MEK inhibitor with an anti-EGFR or anti-ERBB2 agent may be a more effective treatment of ERBB4-dependent, *BRAF* WT melanomas than the combination of a MEK inhibitor with a PI3K inhibitor. We will test these predictions.

**C. Potential mechanisms of specificity in ERBB4-dependent BRAF-WT melanomas.** Here we demonstrate that *ERBB2*, but not *EGFR*, is necessary for clonogenic proliferation of MEL-JUSO cells. This specificity may not be shared by the IPC-298, MeWo, and SK-MEL-2 cell lines, as *EGFR* but not *ERBB2* may be necessary for the clonogenic proliferation of these other *BRAF* WT melanoma cell lines. Furthermore, differences in the role that *EGFR* and *ERBB2* play in the four *ERBB4*-dependent, *BRAF* WT melanoma cell lines may account for the gender disparity observed in *BRAF* WT melanoma outcomes (Table 2c), particularly since the ERBB4 cytoplasmic domain can translocate to the nucleus and possesses a motif that enables interactions with steroid hormone receptor co-activators [7]. Finally, it would not be surprising if some *ERBB4* gain-of-function mutant alleles found in *BRAF* WT melanoma samples and

elsewhere [7] function through potentiating ERBB4 heterodimerization with ERBB2 but not EGFR or vice versa. Clearly, much experimentation lies ahead to address these pressing questions and to determine whether the observations made using *ERBB4*-dependent, *BRAF* WT melanoma cell lines can be translated into advances in the treatment of *BRAF* WT melanomas.

## Tables

	Cases	% of Total Cases	<i>BRAF</i> V600 Mutant Cases	% of <i>BRAF</i> V600 Mutant Cases	<i>BRAF</i> WT Cases	% of <i>BRAF</i> WT Cases
<b>Gender</b>	470		210		227	
Male	290	61.70%	126	60.00%	141	62.11%
Female	180	38.30%	84	40.00%	86	37.89%
<b>Race</b>	470		210		227	
White	447	95.11%	203	96.67%	211	92.95%
Asian	12	2.55%	2	0.95%	10	4.41%
Black or African American	1	0.21%	0	0.00%	1	0.44%
Not Reported	10	2.13%	5	2.38%	5	2.20%
<b>Ethnicity</b>	470		210		227	
Hispanic or Latino	11	2.34%	6	2.86%	4	1.76%
Not Hispanic or Latino	446	94.89%	197	93.81%	217	95.59%
Not Reported	13	2.77%	7	3.33%	6	2.64%
<b>Vital Status</b>	470		210		227	
Alive	249	52.98%	119	56.67%	112	49.34%
Dead	221	47.02%	91	43.33%	115	50.66%
Not Reported	0	0.00%	0	0.00%	0	0.00%
<b>Age at Diagnoses</b>	470		210		227	
<30 (10950 days)	21	4.47%	19	9.05%	2	0.88%
30-49 (10951-17885 days)	106	22.55%	59	28.10%	46	20.26%
50-64 (17886-23360 days)	157	33.40%	80	38.10%	70	30.84%
65+ (>23360 days)	178	37.87%	48	22.86%	106	46.70%
Not Reported	8	1.70%	4	1.90%	3	1.32%
<b>AJCC Pathologic Stage</b>	470		210		227	
0	7	1.49%	2	0.95%	5	2.20%
I	30	6.38%	18	8.57%	12	5.29%
IA	18	3.83%	6	2.86%	10	4.41%
IB	29	6.17%	13	6.19%	14	6.17%
II	30	6.38%	14	6.67%	12	5.29%
IIA	18	3.83%	8	3.81%	8	3.52%
IIB	28	5.96%	5	2.38%	19	8.37%
IIC	64	13.62%	29	13.81%	32	14.10%
III	41	8.72%	22	10.48%	15	6.61%
IIIA	16	3.40%	8	3.81%	6	2.64%
IIIB	46	9.79%	20	9.52%	25	11.01%
IIIC	68	14.47%	25	11.90%	40	17.62%
IV	23	4.89%	12	5.71%	10	4.41%
Not Reported	52	11.06%	28	13.33%	19	8.37%
<b>AJCC Pathologic Stage</b>	390		182		208	
0	7	1.79%	2	1.10%	5	2.40%
I, IA, IB	77	19.74%	37	20.33%	36	17.31%
II, IIA, IIB, IIC	140	35.90%	56	30.77%	71	34.13%
III, IIIA, IIIB, IIIC	171	43.85%	75	41.21%	86	41.35%
IV	23	5.90%	12	6.59%	10	4.81%

**Table 1.** Comparison of demographic and clinicopathologic characteristics of *BRAF* V600X and *BRAF* WT melanoma cases in the TCGA-SKCM dataset.



	BRAF V600X	BRAF WT	Total
Alive	119	112	231
Dead	91	115	206
Total	210	227	437

$P = 0.1252$

**Table 2a.** Comparison of survival among *BRAF* V600X and *BRAF* WT melanoma cases in the TCGA-SKCM dataset.

		BRAF V600X	BRAF WT	Total
AJCC Pathologic Stage at Diagnosis	0	2	5	7
	I, IA, IB	37	36	73
	II, IIA, IIB, IIC	56	71	127
	III, IIIA, IIIB, IIIC	75	86	161
	IV	12	10	22
Total		182	208	390

$P = 0.6842$

**Table 2b.** Comparison of AJCC pathological stage among *BRAF* V600X and *BRAF* WT melanoma cases in the TCGA-SKCM dataset.

	Alive	Deceased	Total
Female	50	36	86
Male	62	79	141
Total	112	115	227

$p = 0.0383$

**Table 2c.** Association of gender with mortality among the *BRAF* WT melanoma cases in the TCGA-SKCM dataset.

	Elevated ERBB4 Expression	Not Elevated ERBB4 Expression	Total
<i>RAS</i> or <i>NF1</i> Nonsynonymous Mutation	21	104	125
<i>RAS</i> and <i>NF1</i> WT	1	52	53
Total	22	156	178

$P = 0.0057$

**Table 2d.** Elevated *ERBB4* transcription is correlated with a gain-of-function *RAS* gene mutation or a loss-of-function *NF1* mutation in *BRAF* WT melanomas of the TCGA-SKCM dataset.

Cell Line	Gender	Origin	Driver Mutations		ERBB4 Mutation(s)
			<i>BRAF/NF1/RAS</i>	<i>PIK3CA/PTEN</i>	
IPC-298	Female	Primary	<i>NRAS</i> Q61L		None
MEL-JUSO	Female	Primary	<i>NRAS</i> Q61L/ <i>HRAS</i> G13D/ <i>NF1</i> L1779P		None
MeWo	Male	Metastasis	<i>NF1</i> Q1336*/ <i>NF1</i> R2053R		M766I/S449F
SK-MEL-2	Male	Metastasis	<i>NRAS</i> Q61R		R50C

Cell Line	Transcription of ERBB Receptor Genes				Transcription of Selected ERBB4 Ligand Genes				
	<i>EGFR</i>	<i>ERBB2</i>	<i>ERBB3</i>	<i>ERBB4</i>	<i>NRG1</i>	<i>NRG2</i>	<i>HBEGF</i>	<i>BTC</i>	<i>EREG</i>
IPC-298	0.07	3.58	6.18	<0.01	0.03	1.36	1.76	<0.01	0.01
MEL-JUSO	0.97	3.87	5.95	0.12	3.67	2.02	6.42	0.26	0.04
MeWo	1.43	4.74	6.59	0.69	1.01	0.28	2.05	0.46	0.03
SK-MEL-2	0.06	3.18	6.74	0.01	0.77	0.73	4.49	<0.01	<0.01

**Table 3.** The commercially available *BRAF* WT melanoma cell lines used in this study do not possess *BRAF*, *PIK3CA*, or *PTEN* mutations, but do possess *NRAS*, *HRAS*, and/or *NF1* mutations. These cell lines exhibit distinct patterns of ERBB receptor gene transcription and ERBB4 ligand gene transcription.

Cell Line	Efficiency of Clonogenic Proliferation Relative to Vector		
	Vector Control	<i>ERBB4</i> WT	<i>ERBB4</i> DN
IPC-298	100%	1340% n = 5 <i>p</i> = 0.0256	64% n = 5 <i>p</i> = 0.0082
MEL-JUSO	100%	389% n = 9 <i>p</i> = 0.002	35% n = 10 <i>p</i> = 5.1E-7
MeWo	100%	563% n = 5 <i>p</i> = 0.0173	29% n = 5 <i>p</i> = 0.0003
SK-MEL-2	100%	159% n = 4 <i>p</i> = 0.0158	47% n = 5 <i>p</i> = 0.0127

**Table 4.** In the *BRAF* WT IPC-298, MEL-JUSO, MeWo, and SK-MEL-2 cell lines, *ERBB4* WT causes a statistically significant increase in clonogenic proliferation, whereas *ERBB4* DN causes a statistically significant decrease in clonogenic proliferation.


	Vector	WT	DN
Average (um)	83	83	69
SEM (um)	3	3	2
Median (um)	78	77	63
P-value: T-test (Relative to Vector)		0.483	1.932E-04
N (colonies)	324	323	326

**Table 5.** *ERBB4* DN causes a significant decrease in the size of anchorage-independent colonies of MEL-JUSO cells.


Efficiency of Clonogenic Proliferation Relative to Vector		
<i>Virus</i>	<i>Average (n=4)</i>	<i>One-Sample t Test</i>
LXSN	100%	
<i>ERBB4</i> WT	233%	0.064
<i>EGFR</i> WT	244%	0.011
<i>EGFR</i> DN	144%	0.485
<i>ERBB2</i> WT	222%	0.047
<i>ERBB2</i> DN	54%	0.140

**Table 6.** In the *BRAF* WT MEL-JUSO cell line, *EGFR* WT and *ERBB2* WT cause an increase in clonogenic proliferation, whereas *ERBB2* DN causes a decrease in clonogenic proliferation.

## Figures



**Figure 1.** Twenty-two (12%) of the available *BRAF* WT melanomas of the TCGA-SKCM dataset exhibit *ERBB4* transcription of greater than or equal to 0.12.




**Figure 2.** The MeWo cell line expresses the canonical JMa/Cyt1 *ERBB4* transcriptional splicing isoform.




**Data are forthcoming.**


**Figure 3.** The ERBB4 K751M mutant protein exhibits much less tyrosine phosphorylation than the wild-type ERBB4 protein.



**Figure 4.** In the MEL-JUSO cell line, stable infection with LXS-ERBB4-WT causes increased clonogenic proliferation, whereas stable infection with LXS-ERBB4-DN causes decreased clonogenic proliferation.



**Figure 5.** MEL-JUSO cells infected with the LXS<sup>N</sup>- ERBB4-DN retrovirus form smaller anchorage-independent colonies (right panel) than do MEL-JUSO cells infected with the LXS<sup>N</sup> vector control retrovirus (left panel).



**Figure 6.** We hypothesize that signaling by ERBB4-EGFR or ERBB4-ERBB2 heterodimers can be stimulated by ERBB4 ligands, ERBB4 overexpression, or ERBB4 mutations, resulting in increased signaling by the PI3K pathway, which cooperates with elevated RAS/MAPK pathway signaling to drive the proliferation of *BRAF* WT melanomas.

## References

1. *NCCN Clinical Practice Guidelines in Oncology - Melanoma, Cutaneous Version 2.2023*. March 10, 2023 [Accessed June 12, 2023]; Available from: [https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf).
2. Schummer, P., B. Schilling, and A. Gesierich, *Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?* *Am J Clin Dermatol*, 2020. **21**(4): p. 493-504.
3. Robert, C., et al., *Pembrolizumab versus Ipilimumab in Advanced Melanoma*. *N Engl J Med*, 2015. **372**(26): p. 2521-32.
4. Larkin, J., et al., *Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma*. *N Engl J Med*, 2019. **381**(16): p. 1535-1546.
5. Dummer, R., et al., *Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review*. *JAMA Oncol*, 2020. **6**(12): p. 1957-1966.
6. Swetter, S.M., et al., *NCCN Guidelines(R) Insights: Melanoma: Cutaneous, Version 2.2021*. *J Natl Compr Canc Netw*, 2021. **19**(4): p. 364-376.
7. Lucas, L.M., et al., *The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein*. *Pharmacol Rev*, 2022. **74**(1): p. 18-47.
8. Tian, X., et al., *Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer*. *Biochim Biophys Acta Rev Cancer*, 2022. **1877**(1): p. 188645.
9. Reita, D., et al., *Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring*. *Cancers (Basel)*, 2021. **13**(19).
10. Tsubata, Y., R. Tanino, and T. Isobe, *Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance*. *Cells*, 2021. **10**(11).
11. Di Noia, V., et al., *Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies*. *ESMO Open*, 2021. **6**(6): p. 100280.
12. Zhou, J., Q. Ji, and Q. Li, *Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies*. *J Exp Clin Cancer Res*, 2021. **40**(1): p. 328.
13. Melosky, B., et al., *The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer*. *Ther Adv Med Oncol*, 2021. **13**: p. 17588359211056306.
14. Chen, J., M. Colosimo, and E. Lim, *The management of HER2-positive early breast cancer: Current and future therapies*. *Asia Pac J Clin Oncol*, 2021. **17 Suppl 6**: p. 3-12.
15. Wu, H.X., K.Q. Zhuo, and K. Wang, *Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis*. *Br J Clin Pharmacol*, 2022. **88**(5): p. 2019-2034.
16. Salkeni, M.A., et al., *Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer*. *Breast Cancer (Dove Med Press)*, 2021. **13**: p. 539-557.
17. You, Z., et al., *Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis*. *Cancer Cell Int*, 2021. **21**(1): p. 489.

18. Pupa, S.M., et al., *HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness*. *Cancers* (Basel), 2021. **13**(19).
19. Li, L., et al., *Antibody-drug conjugates in HER2-positive breast cancer*. *Chin Med J (Engl)*, 2021. **135**(3): p. 261-267.
20. Hrynchak, I., et al., *Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies*. *Int J Mol Sci*, 2021. **22**(19).
21. Fatima, I., et al., *Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy*. *J Funct Biomater*, 2021. **12**(4).
22. Azar, I., et al., *Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer*. *Lung Cancer* (Auckl), 2021. **12**: p. 103-114.
23. Vathiotis, I.A., et al., *HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy*. *Pharmaceuticals* (Basel), 2021. **14**(12).
24. Hafeez, U., et al., *New insights into ErbB3 function and therapeutic targeting in cancer*. *Expert Rev Anticancer Ther*, 2020. **20**(12): p. 1057-1074.
25. Kiavue, N., et al., *ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics*. *Oncogene*, 2020. **39**(3): p. 487-502.
26. *NCI GDC Data Portal: TCGA-SKCM Skin Cutaneous Melanoma Data Set*. [Accessed June 15, 2022]; Available from: <https://portal.gdc.cancer.gov/projects/TCGA-SKCM>.
27. Miller, J.G. and S. Mac Neil, *Gender and cutaneous melanoma*. *Br J Dermatol*, 1997. **136**(5): p. 657-65.
28. Bellenghi, M., et al., *Sex and Gender Disparities in Melanoma*. *Cancers* (Basel), 2020. **12**(7).
29. Schwartz, M.R., L. Luo, and M. Berwick, *Sex Differences in Melanoma*. *Curr Epidemiol Rep*, 2019. **6**(2): p. 112-118.
30. Duma, N., et al., *Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?* *Oncologist*, 2019. **24**(11): p. e1148-e1155.
31. Yang, C., et al., *Androgen receptor-mediated CD8(+) T cell stemness programs drive sex differences in antitumor immunity*. *Immunity*, 2022. **55**(7): p. 1268-1283 e9.
32. Yang, C., et al., *Androgen receptor-mediated CD8(+) T cell stemness programs drive sex differences in antitumor immunity*. *Immunity*, 2022. **55**(9): p. 1747.
33. Ma, M., et al., *Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis*. *J Exp Med*, 2021. **218**(2).
34. Joosse, A., et al., *Gender differences in melanoma survival: female patients have a decreased risk of metastasis*. *J Invest Dermatol*, 2011. **131**(3): p. 719-26.
35. Vellano, C.P., et al., *Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy*. *Nature*, 2022. **606**(7915): p. 797-803.
36. Morgese, F., et al., *Gender Differences and Outcomes in Melanoma Patients*. *Oncol Ther*, 2020. **8**(1): p. 103-114.
37. Al Mahi, A. and J. Ablain, *RAS pathway regulation in melanoma*. *Dis Model Mech*, 2022. **15**(2).
38. Liu, C.Y., et al., *Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers*. *J Chin Med Assoc*, 2022. **85**(4): p. 409-413.



39. Smith, C.I.E. and J.A. Burger, *Resistance Mutations to BTK Inhibitors Originate From the NF-kappaB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway*. *Front Immunol*, 2021. **12**: p. 689472.
40. Huang, X.L., et al., *Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision*. *Int J Biol Macromol*, 2021. **180**: p. 739-752.
41. Oliveres, H., D. Pesantez, and J. Maurel, *Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients*. *Int J Mol Sci*, 2021. **22**(9).
42. Santos, E.D.S., et al., *EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles*. *Int J Pharm*, 2021. **592**: p. 120082.
43. Zhao, Y., H. Wang, and C. He, *Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy*. *J Cancer Res Clin Oncol*, 2021. **147**(12): p. 3653-3664.
44. Barbosa, R., L.A. Acevedo, and R. Marmorstein, *The MEK/ERK Network as a Therapeutic Target in Human Cancer*. *Mol Cancer Res*, 2021. **19**(3): p. 361-374.
45. Prickett, T.D., et al., *Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4*. *Nat Genet*, 2009. **41**(10): p. 1127-32.
46. *Broad Institute Cancer Cell Line Encyclopedia*. [Accessed Feb 6, 2023]; Available from: <https://sites.broadinstitute.org/ccle/>.
47. *COLO-792 - ECACC # 93052616*. [Accessed Feb 6, 2023]; Available from: [https://www.culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=93052616&collection=ecacc\\_gc](https://www.culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=93052616&collection=ecacc_gc).
48. *HMCB - ATCC # CRL-9607*. [Accessed Feb 6, 2023]; Available from: <https://www.atcc.org/products/crl-9607>.
49. *IPC-298 - DSMZ # ACC 251*. [Accessed Feb 23, 2023]; Available from: <https://www.dsmz.de/collection/catalogue/details/culture/ACC-251>.
50. *MEL-JUSO - DSMZ # ACC 74*. [Accessed Feb 23, 2023]; Available from: <https://www.dsmz.de/collection/catalogue/details/culture/ACC-74>.
51. *MeWo - ATCC # HTB-65*. [Accessed June 15, 2022]; Available from: <https://www.atcc.org/products/htb-65>.
52. *SK-MEL-2 - ATCC # HTB-68*. [Accessed Feb 6, 2023]; Available from: <https://www.atcc.org/products/htb-68>.
53. Wilson, K.J., et al., *The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist*. *Biochem J*, 2012. **443**(1): p. 133-44.
54. Honegger, A.M., et al., *Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation*. *Proc Natl Acad Sci U S A*, 1989. **86**(3): p. 925-9.
55. Samarakoon, R. and P.J. Higgins, *The Cytoskeletal Network Regulates Expression of the Profibrotic Genes PAI-1 and CTGF in Vascular Smooth Muscle Cells*. *Adv Pharmacol*, 2018. **81**: p. 79-94.
56. Wu, D., et al., *EGFR-PLCgamma1 signaling mediates high glucose-induced PKCbeta1-Akt activation and collagen I upregulation in mesangial cells*. *Am J Physiol Renal Physiol*, 2009. **297**(3): p. F822-34.



57. Samarakoon, R., et al., *TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling*. *J Mol Cell Cardiol*, 2008. **44**(3): p. 527-38.
58. Honegger, A.M., et al., *Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells*. *Mol Cell Biol*, 1990. **10**(8): p. 4035-44.
59. Mill, C.P., et al., *ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer*. *Genes Cancer*, 2011. **2**(8): p. 792-804.
60. Ren, X.R., et al., *Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells*. *Breast Cancer Res*, 2012. **14**(3): p. R89.
61. Akiyama, T., et al., *The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain*. *Mol Cell Biol*, 1991. **11**(2): p. 833-42.
62. Messerle, K., et al., *NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant*. *Mol Cell Endocrinol*, 1994. **105**(1): p. 1-10.
63. Williams, E.E., et al., *A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines*. *Cancer Lett*, 2003. **192**(1): p. 67-74.
64. Gallo, R.M., et al., *Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant*. *J Cancer Res Ther Oncol*, 2013. **1**(1): p. 10.
65. Pitfield, S.E., et al., *Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines*. *Oncol Res*, 2006. **16**(4): p. 179-93.
66. Mill, C.P., K.L. Gettinger, and D.J. Riese, 2nd, *Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines*. *Exp Cell Res*, 2011. **317**(4): p. 392-404.
67. Penington, D.J., I. Bryant, and D.J. Riese, 2nd, *Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities*. *Cell Growth Differ*, 2002. **13**(6): p. 247-56.
68. Gallo, R.M., et al., *Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines*. *Biochem Biophys Res Commun*, 2006. **349**(1): p. 372-82.
69. Wilson, K.J., et al., *Inter-conversion of neuregulin2 full and partial agonists for ErbB4*. *Biochem Biophys Res Commun*, 2007. **364**(2): p. 351-7.
70. Riese, D.J., 2nd, et al., *Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2*. *J Biol Chem*, 1998. **273**(18): p. 11288-94.
71. Riese, D.J., 2nd, et al., *The cellular response to neuregulins is governed by complex interactions of the erbB receptor family*. *Mol Cell Biol*, 1995. **15**(10): p. 5770-6.
72. Hobbs, S.S., et al., *Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation*. *Oncogene*, 2002. **21**(55): p. 8442-52.

73. Hobbs, S.S., et al., *Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase*. *Oncogene*, 2004. **23**(4): p. 883-93.
74. *NCI Genomic Data Commons (GDC) Portal*. [Accessed June 15, 2022]; Available from: <https://portal.gdc.cancer.gov/>.
75. *The R Project for Statistical Computing*. [Accessed June 15, 2022]; Available from: <https://www.r-project.org>.
76. *GraphPad Prism*. [Accessed June 15, 2022]; Available from: <https://www.graphpad.com>.
77. *Microsoft Excel*. [Accessed June 21, 2023]; Available from: <https://www.microsoft.com/en-us/microsoft-365/excel>.
78. Riese, D.J., 2nd, et al., *Bovine papillomavirus E2 repressor mutant displays a high-copy-number phenotype and enhanced transforming activity*. *J Virol*, 1990. **64**(2): p. 944-9.
79. Mann, R., R.C. Mulligan, and D. Baltimore, *Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus*. *Cell*, 1983. **33**(1): p. 153-9.
80. Miller, A.D. and C. Buttimore, *Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production*. *Mol Cell Biol*, 1986. **6**(8): p. 2895-902.
81. Riese, D.J., 2nd and D. DiMaio, *An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein*. *Oncogene*, 1995. **10**(7): p. 1431-9.
82. Leptak, C., et al., *Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16*. *J Virol*, 1991. **65**(12): p. 7078-83.
83. *DSMZ*. [Accessed June 15, 2022]; Available from: <https://www.dsmz.de>.
84. *ATCC - American Type Culture Collection*. [Accessed June 12, 2023]; Available from: <https://www.atcc.org/>.
85. *Cytiva*. [Accessed June 15, 2022]; Available from: <https://www.cytivalifesciences.com/en/us/shop>.
86. *Corning*. [Accessed June 15, 2022]; Available from: <https://www.corning.com/worldwide/en/products/life-sciences.html>.
87. Miller, A.D. and G.J. Rosman, *Improved retroviral vectors for gene transfer and expression*. *Biotechniques*, 1989. **7**(9): p. 980-2, 984-6, 989-90.
88. Hwang, E.S., et al., *Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene*. *J Virol*, 1993. **67**(7): p. 3720-9.
89. *NIH ImageJ*. [Accessed May 12, 2023]; Available from: <https://imagej.nih.gov/ij/download.html>.
90. Nunnery, S.E. and I.A. Mayer, *Management of toxicity to isoform alpha-specific PI3K inhibitors*. *Ann Oncol*, 2019. **30**(Suppl\_10): p. x21-x26.
91. Greenwell, I.B., A. Ip, and J.B. Cohen, *PI3K Inhibitors: Understanding Toxicity Mechanisms and Management*. *Oncology (Williston Park)*, 2017. **31**(11): p. 821-8.